KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

West Pharmaceutical Services (WST) Accumulated Depreciation & Amortization (2016 - 2025)

West Pharmaceutical Services' Accumulated Depreciation & Amortization history spans 17 years, with the latest figure at $171.4 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 10.3% year-over-year to $171.4 million; the TTM value through Dec 2025 reached $171.4 million, up 10.3%, while the annual FY2025 figure was $171.4 million, 10.3% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $171.4 million at West Pharmaceutical Services, up from $124.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.3 billion in Q3 2023 and bottomed at $35.6 million in Q1 2024.
  • The 5-year median for Accumulated Depreciation & Amortization is $163.4 million (2024), against an average of $594.3 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization grew 13.85% in 2023 before it plummeted 97.18% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $122.3 million in 2021, then dropped by 1.39% to $120.6 million in 2022, then increased by 13.85% to $137.3 million in 2023, then grew by 13.18% to $155.4 million in 2024, then increased by 10.3% to $171.4 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Accumulated Depreciation & Amortization are $171.4 million (Q4 2025), $124.4 million (Q3 2025), and $81.4 million (Q2 2025).